RevMed maps its next RAS frontier

With clinical data cementing the value of its tri-complex RAS inhibition platform, RevMed’s story is shifting from whether the platform works to how far the company can extend it. The San Francisco Bay Area biotech is laying the groundwork for a future in which mechanistic combinations and catalytic inhibition forestall resistance, and where its therapies could move all the way up the treatment continuum to disease interception.

Through a stream of readouts over the past year, Revolution Medicines Inc. (NASDAQ:RVMD) has deepened its pipeline’s reach across multiple disease settings. The capstone came with April 13 top-line data from its RASolute 302 trial, in which multi-RAS inhibitor daraxonrasib nearly doubled overall survival versus chemotherapy in second-line pancreatic ductal adenocarcinoma (PDAC), a historically intractable cancer where more than 90% of patients have RAS mutations. “It validates the entire work, and the pipeline beyond that,” Chief Development Officer Alan Sandler told BioCentury...